We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+4.62%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$112B
AUM Growth
+$936M
Cap. Flow
-$1.26B
Cap. Flow %
-1.13%
Top 10 Hldgs %
31.26%
Holding
4,289
New
46
Increased
1,994
Reduced
1,731
Closed
73

Top Buys

Rank Stock Value
1
EXE
Expand Energy Corp
EXE
+$56.7M
2
APO icon
Apollo Global Management
APO
+$36.8M
3
BA icon
Boeing
BA
+$34.1M
4
WDAY icon
Workday
WDAY
+$31.9M
5
DOCU
DocuSign
DOCU
+$26.4M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$136M
2
NVDA icon
NVIDIA
NVDA
+$110M
3
MSFT icon
Microsoft
MSFT
+$84.1M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$48.4M
5
XYZ
Block Inc
XYZ
+$44.9M

Sector Composition

Rank Sector Weight
1 Technology 30.97%
2 Financials 13.53%
3 Consumer Discretionary 11.77%
4 Healthcare 10.06%
5 Industrials 8.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MAG
3226
DELISTED
MAG Silver
MAG
$79.8K ﹤0.01%
5,871
-410
-7% -$6.37K
MASS icon
3227
908 Devices
MASS
$364M
$79.8K ﹤0.01%
36,278
+1,534
+4% +$4.39K
STKS icon
3228
The ONE Group
STKS
$53M
$79.7K ﹤0.01%
27,490
+1,090
+4% +$3.62K
SWKH
3229
DELISTED
SWK Holdings
SWKH
$79.7K ﹤0.01%
6,340
-1,053
-14% -$13.7K
TAYD icon
3230
Taylor Devices
TAYD
$175M
$78.6K ﹤0.01%
1,889
-20
-1% -$910
OVID icon
3231
Ovid Therapeutics
OVID
$491M
$78.5K ﹤0.01%
84,078
+15,355
+22% +$17.2K
INMB icon
3232
INmune Bio
INMB
$57.7M
$78.2K ﹤0.01%
16,744
+2,424
+17% +$12.6K
XBIT icon
3233
XBiotech
XBIT
$69.2M
$78K ﹤0.01%
19,744
-1,506
-7% -$10.3K
GBIO
3234
DELISTED
Generation Bio
GBIO
$77.8K ﹤0.01%
7,345
-217
-3% -$3.87K
ALAR
3235
Alarum Technologies
ALAR
$14.3M
$76.8K ﹤0.01%
7,240
-300
-4% -$3.89K
ULBI icon
3236
Ultralife
ULBI
$106M
$76K ﹤0.01%
10,196
+89
+0.9% +$732
WDH
3237
Waterdrop
WDH
$359M
$74.3K ﹤0.01%
62,993
-6,820
-10% -$7.96K
LCUT icon
3238
Lifetime Brands
LCUT
$211M
$74K ﹤0.01%
12,519
+60
+0.5% +$362
TUSK icon
3239
Mammoth Energy Services
TUSK
$163M
$73.6K ﹤0.01%
24,534
-562
-2% -$2.07K
AKYA
3240
DELISTED
Akoya BioSciences
AKYA
$73.4K ﹤0.01%
32,051
+1,590
+5% +$4.21K
GLSI icon
3241
Greenwich LifeSciences
GLSI
$211M
$73K ﹤0.01%
6,505
+203
+3% +$2.72K
AKA icon
3242
a.k.a. Brands
AKA
$119M
$73K ﹤0.01%
3,900
+3,236
+487% +$70.7K
RAPT
3243
DELISTED
RAPT Therapeutics
RAPT
$73K ﹤0.01%
5,774
XYF
3244
X Financial
XYF
$204M
$72.8K ﹤0.01%
8,745
E icon
3245
ENI
E
$77.5B
$72.7K ﹤0.01%
2,659
EWI icon
3246
iShares MSCI Italy ETF
EWI
$1.07B
$72.7K ﹤0.01%
2,020
-10
-0.5% -$373
DDI
3247
DoubleDown Interactive
DDI
$588M
$72.6K ﹤0.01%
6,950
-1,355
-16% -$18.6K
PRPL icon
3248
Purple Innovation
PRPL
$41.7M
$72.2K ﹤0.01%
3,701
+136
+4% +$3.08K
EVI icon
3249
EVI Industries
EVI
$180M
$71.9K ﹤0.01%
4,396
+148
+3% +$2.82K
PEPG icon
3250
PepGen
PEPG
$197M
$71.8K ﹤0.01%
18,954
+574
+3% +$3.58K

Similar funds

RhumbLine Advisers's Q4 2024 Portfolio in Review

As of Q4 2024, RhumbLine Advisers held 4,289 positions worth $112B, up 0.84% from $111B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Trading was light in Q4 2024: portfolio turnover was 2.8%. RhumbLine Advisers opened 46 new positions and exited 73, leaving the 4,289-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Financials and Consumer Discretionary.

  • RhumbLine Advisers's largest Q4 2024 buy was Expand Energy Corp: 614,703 shares worth $61.2M.
  • RhumbLine Advisers added most to Apollo Global Management in Q4 2024, an estimated $36.8M increase.
  • RhumbLine Advisers's biggest Q4 2024 reduction was Apple, cutting an estimated $136M.
  • RhumbLine Advisers fully exited Block Inc in Q4 2024, selling an estimated $44.9M.
  • RhumbLine Advisers's ten largest holdings make up 31% of its $112B portfolio in Q4 2024.
  • RhumbLine Advisers opened 46 new positions and closed 73 in Q4 2024.
  • RhumbLine Advisers's portfolio value rose 0.84% quarter-over-quarter to $112B.

Based on RhumbLine Advisers's 13F filing for Q4 2024, filed 30 Jan 2025.